Psma3 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
PSMA3 (Proteasome Subunit Alpha Type 3) is a critical component of the 20S proteasome core particle, the proteolytic machinery responsible for degrading ubiquitin-tagged proteins. Also known as proteasome subunit alpha type-3 or HC5, this protein plays an essential role in cellular protein homeostasis, antigen processing, and the clearance of misfolded proteins that accumulate in neurodegenerative diseases. [1]
The proteasome represents a fundamental defense against proteotoxic stress, and dysfunction of this system is increasingly recognized as a key contributor to the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and other neurodegenerative disorders. [2]
PSMA3 consists of 255 amino acids with a molecular weight of approximately 28.1 kDa. The protein contains: [3]
PSMA3 is one of seven α-subunits (PSMA1-7) that form the outer α-ring of the 20S proteasome. This heptameric ring creates a gated channel controlling substrate access to the proteolytic chamber: [4]
The UPS is the primary mechanism for targeted protein degradation in eukaryotic cells: [5]
PSMA3 is essential for proper 20S proteasome assembly: [6]
The α-ring, including PSMA3, controls substrate entry through: [7]
Proteasome function is impaired in AD brain: [8]
The proteasome is critically involved in PD: [9]
ALS features prominent proteasome dysfunction:
Proteasome impairment contributes to HD:
Reactive oxygen species (ROS) can:
Kinases can modulate proteasome activity:
Protein aggregates can:
Drug development focuses on:
Rational combinations include:
Proteasome measurements may serve as:
PSMA3 represents a critical node in cellular protein homeostasis. As a core component of the 20S proteasome α-ring, it is essential for gate regulation and substrate entry. Proteasome dysfunction is increasingly recognized as a common feature of neurodegenerative diseases, making PSMA3 and related proteins attractive therapeutic targets. Understanding the precise mechanisms of proteasome impairment and developing strategies to enhance proteasome function remain active areas of research with significant clinical implications.
Psma3 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Psma3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Ciechanover A, The ubiquitin-proteasome system (2015). 2015. ↩︎
Ding Q et al. Proteasome in neurodegeneration (2019). 2019. ↩︎
Tai HC et al. Proteasome dysfunction in neurodegeneration (2012). 2012. ↩︎
Bedford L et al. Protein aggregates in neurodegeneration (2011). 2011. ↩︎
Kakkar V et al. Proteostasis and neurodegeneration (2014). 2014. ↩︎
Lim KH et al. Proteasome activity in Alzheimer's disease (2021). 2021. ↩︎
McKinnon C et al. Alpha-synuclein and proteasome (2022). 2022. ↩︎
Chen T et al. Proteasome activators for neurodegenerative disease (2023). 2023. ↩︎
Bingol B, Autophagy and proteasome crosstalk (2014). 2014. ↩︎